Sort   by:  
 Page size 
UnknownOlaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Not available
S-EPMC6057749 | biostudies-literature
UnknownIdentification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
Not available
S-EPMC7303595 | biostudies-literature
UnknownAssociation Between Statin Use at the Time of Intra-abdominal Surgery and Postoperative Adhesion-Related Complications and Small-Bowel Obstruction.
Not available
S-EPMC7859844 | biostudies-literature
UnknownFDG PET/CT Imaging 1 Week after a Single Dose of Pembrolizumab Predicts Treatment Response in Patients with Advanced Melanoma.
Not available
S-EPMC11062839 | biostudies-literature
UnknownConcurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma.
Not available
S-EPMC3956616 | biostudies-literature
UnknownCombination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8<sup>+</sup> T cells.
Not available
S-EPMC11387127 | biostudies-literature
UnknownTargeting quiescent leukemic stem cells using second generation autophagy inhibitors.
Not available
S-EPMC6292500 | biostudies-literature
UnknownImmunologic Predictors of Vaccine Responsiveness in Patients With Lymphoma and Chronic Lymphocytic Leukemia.
Not available
S-EPMC11272091 | biostudies-literature
UnknownA single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.
Not available
S-EPMC6699626 | biostudies-literature
UnknownT-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Not available
S-EPMC5554367 | biostudies-literature
Sort   by:  
 Page size